IOVA Quote, Financials, Valuation and Earnings

Day One Biopharmaceuticals, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of -49.57%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Day One Biopharmaceuticals, Inc.'s return on equity of -30.98%.

Iovance Biotherapeutics, Inc. has a consensus price target of $8.35, signalling upside risk potential of 196.1%. On the other hand Day One Biopharmaceuticals, Inc. has an analysts' consensus of $22.25 which suggests that it could grow by 131.05%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Day One Biopharmaceuticals, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Day One Biopharmaceuticals, Inc..

Iovance Biotherapeutics, Inc. has a beta of 0.827, which suggesting that the stock is 17.288% less volatile than S&P 500. In comparison Day One Biopharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Day One Biopharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Day One Biopharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than Day One Biopharmaceuticals, Inc. quarterly revenues of $39.8M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Day One Biopharmaceuticals, Inc.'s net income of -$19.7M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Day One Biopharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.73x versus 7.39x for Day One Biopharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Technologies, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of -2.7%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat iRhythm Technologies, Inc.'s return on equity of -54.18%.

Iovance Biotherapeutics, Inc. has a consensus price target of $8.35, signalling upside risk potential of 196.1%. On the other hand iRhythm Technologies, Inc. has an analysts' consensus of $218.60 which suggests that it could grow by 22.5%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than iRhythm Technologies, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than iRhythm Technologies, Inc..

Iovance Biotherapeutics, Inc. has a beta of 0.827, which suggesting that the stock is 17.288% less volatile than S&P 500. In comparison iRhythm Technologies, Inc. has a beta of 1.099, suggesting its more volatile than the S&P 500 by 9.93%.

Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. iRhythm Technologies, Inc. pays out -- of its earnings as a dividend.

Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are smaller than iRhythm Technologies, Inc. quarterly revenues of $192.9M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than iRhythm Technologies, Inc.'s net income of -$5.2M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while iRhythm Technologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.73x versus 8.07x for iRhythm Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lantheus Holdings, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of 7.23%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Lantheus Holdings, Inc.'s return on equity of 14.66%.

Iovance Biotherapeutics, Inc. has a consensus price target of $8.35, signalling upside risk potential of 196.1%. On the other hand Lantheus Holdings, Inc. has an analysts' consensus of $82.43 which suggests that it could grow by 23.9%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Lantheus Holdings, Inc..

Iovance Biotherapeutics, Inc. has a beta of 0.827, which suggesting that the stock is 17.288% less volatile than S&P 500. In comparison Lantheus Holdings, Inc. has a beta of -0.102, suggesting its less volatile than the S&P 500 by 110.17%.

Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lantheus Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Lantheus Holdings, Inc. pays out -- of its earnings as a dividend.

Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are smaller than Lantheus Holdings, Inc. quarterly revenues of $384M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Lantheus Holdings, Inc.'s net income of $27.8M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Lantheus Holdings, Inc.'s PE ratio is 27.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.73x versus 3.04x for Lantheus Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of -316.61%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Plus Therapeutics, Inc.'s return on equity of --.

Iovance Biotherapeutics, Inc. has a consensus price target of $8.35, signalling upside risk potential of 196.1%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $7.16 which suggests that it could grow by 1203.97%. Given that Plus Therapeutics, Inc. has higher upside potential than Iovance Biotherapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Iovance Biotherapeutics, Inc..

Iovance Biotherapeutics, Inc. has a beta of 0.827, which suggesting that the stock is 17.288% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.692%.

Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.73x versus 8.80x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.